Intended for healthcare professionals

  1. Research
  2. Selective serotonin...
  3. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
CCBYNC Open access
Research

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c693 (Published 09 February 2010) Cite this as: BMJ 2010;340:c693

Data supplement

  • Web Extra

    Extra material supplied by the author

    Files in this Data Supplement:

    • Data Supplement - Appendix 1: Cohort assembly
    • Data Supplement - Appendix 2: Characteristics of tamoxifen and antidepressant use
    • Data Supplement - Appendix 3: Other antidepressant use among women receiving SSRIs during tamoxifen treatment

Related articles

See more

Cited by...

  • Advances in the care of breast cancer survivors
  • Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
  • Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants
  • Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study
  • Revisiting the drug interaction between tamoxifen and SSRI antidepressants
  • Antidepressants and Platinum Drugs
  • Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
  • Tamoxifen and CYP2D6: A Contradiction of Data
  • Acupuncture for Hot Flashes: Decision Making by Breast Cancer Survivors
  • Hormone replacement therapy
  • The effect of MELatOnin on Depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: protocol for a randomised, placebo-controlled, double-blinded trial
  • Exercise Effects on Depressive Symptoms in Cancer Survivors: A Systematic Review and Meta-analysis
  • Healthcare Professional Students Knowledge of Drug-Drug Interactions
  • Hot Flashes: A Review of Pathophysiology and Treatment Modalities
  • Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials
  • Symptom Management in Metastatic Breast Cancer
  • Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment
  • Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
  • Pharmacy Students Retention of Knowledge of Drug-Drug Interactions
  • Critical issues associated with drug-drug interactions: Highlights of a multistakeholder conference
  • Aromatase Inhibitors as Adjuvant Therapy for Breast Cancer
  • Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors
  • Reply to R. Ferraldeschi et al
  • Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen
  • Authors' reply
  • Why condemn fluoxetine?
  • Do Selective Serotonin Reuptake Inhibitors Attenuate Tamoxifen's Benefits in Breast Cancer Survivors?
  • Paroxetine Use Negates Benefits of Tamoxifen in Women with Breast Cancer
  • Interaction of serotonin reuptake inhibitors with tamoxifen
Back to top